E-21R

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameE-21R
Drug Alias NameE-21R
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionApoptosis stimulantsColony stimulating factor antagonistsImmunosuppressants
TargetsColony stimulating factor
Therapy Area/IndicationsArthritis, RheumatoidLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHanson Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanson InstituteHospira Inc
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid

Other Information

ATC CodeN/A
Related LinksN/A